Lercanidipine Orion (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium entry that is necessary for contraction. This results in relaxation of arterial walls, decreased peripheral resistance, and ultimately a reduction in systolic and diastolic blood pressure.

The appropriate dose of Lercanidipine Orion is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant therapies. Dosage adjustments are made during treatment to achieve target blood‑pressure goals while minimizing adverse effects.

Safety data for lercanidipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and alternative therapies are preferred when possible.

To place an order, submit an enquiry on the Lercanidipine Orion product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine calcium‑channel blocker class and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may cause less peripheral edema in some patients, while amlodipine is more widely studied. Choice depends on individual response, tolerability and physician preference.

Lercanidipine Orion tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually once daily, with a glass of water. It may be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any specific dietary considerations.

Serious adverse events, although rare, include severe hypotension, angioedema, and myocardial infarction. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, swelling of the face or throat, or chest pain while on therapy.

Lercanidipine Orion is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation, in those with severe aortic stenosis, and in individuals experiencing cardiogenic shock. Caution is also advised for patients with significant hepatic impairment.